

CITATION REPORT

List of articles citing

Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria

DOI: 10.1007/s40273-016-0412-1
Pharmacoeconomics, 2016, 34, 815-27.

Source: <https://exaly.com/paper-pdf/64019301/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
26	[Diagnostic and Therapeutic Approach of Chronic Spontaneous Urticaria: Recommendations in Portugal]. <i>Acta Medica Portuguesa</i> , 2016 , 29, 763-781	1.4	3
25	Omalizumab cost effective for chronic urticaria in UK. <i>PharmacoEconomics & Outcomes News</i> , 2016 , 754, 20-20	0.1	
24	Omalizumab for the Treatment of Chronic Idiopathic Urticaria: Systematic Review of the Literature. <i>Pharmacotherapy</i> , 2017 , 37, 464-480	5.8	36
23	The Expanding Field of Biologics in the Management of Chronic Urticaria. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017 , 5, 1489-1499	5.4	12
22	Management of chronic spontaneous urticaria (CSU): a treat to target approach using a patient reported outcome. <i>Allergy, Asthma and Clinical Immunology</i> , 2017 , 13, 38	3.2	4
21	Cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria. <i>British Journal of Dermatology</i> , 2018 , 179, 702-708	4	11
20	The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018 , 73, 1393-1414	9.3	681
19	EAACI/GA2LEN/EDF/WAO-Leitlinie für die Definition, Klassifikation, Diagnose und das Management der Urtikaria [konsentierter, deutschsprachiger Übersetzung]. <i>Allergo Journal</i> , 2018 , 27, 41-69	0	2
18	Two decades with omalizumab: what we still have to learn. <i>Biologics: Targets and Therapy</i> , 2018 , 12, 135-142	4.2	15
17	Improvements in quality of life and work productivity make omalizumab cost-effective for the treatment of chronic spontaneous urticaria. <i>British Journal of Dermatology</i> , 2018 , 179, 562-563	4	
16	[Omalizumab for the treatment of chronic urticaria: Real-life findings]. <i>Annales De Dermatologie Et De Venereologie</i> , 2019 , 146, 9-18	0.3	1
15	Consensus on the diagnostic and therapeutic management of chronic spontaneous urticaria in adults - Brazilian Society of Dermatology. <i>Anais Brasileiros De Dermatologia</i> , 2019 , 94, 56-66	1.6	1
14	Angioedema and prescribing of omalizumab for chronic urticaria in countries with limited financial resources. <i>World Allergy Organization Journal</i> , 2019 , 12, 100079	5.2	2
13	Wytyczne EAACI/GA2LEN/EDF/WAO dotyczące definicji, klasyfikacji, diagnostyki i leczenia pokrzywki. <i>Alergologia Polska - Polish Journal of Allergology</i> , 2020 , 7, 1-28	0.1	1
12	Economic considerations on the usage of biologics in the allergy clinic. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021 , 76, 191-209	9.3	4
11	Analysis of the long-term economic burden of omalizumab on patients with chronic spontaneous urticaria. <i>Journal of Dermatology</i> , 2021 , 48, 56-63	1.6	1
10	EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021 ,	9.3	0

9	The international EAACI/GA \square LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021 ,	9.3	50
8	Lachnospira is a signature of antihistamine efficacy in chronic spontaneous urticaria. <i>Experimental Dermatology</i> , 2021 ,	4	1
7	The EAACI/GA \square LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. <i>Alergologia</i> , 2021 , 4, 155	0	0
6	Short-term effects of multiple ozone metrics on outpatient visits for urticaria in Lanzhou, China. <i>Stochastic Environmental Research and Risk Assessment</i> , 1	3.5	
5	Immunological signature of chronic spontaneous urticaria (Review).. <i>Experimental and Therapeutic Medicine</i> , 2022 , 23, 381	2.1	1
4	Real-world safety and effectiveness of omalizumab in Japanese patients with chronic spontaneous urticaria: A post-marketing surveillance study. 2022 ,		0
3	Acupuncture and Related Therapies for Chronic Urticaria: A Critical Overview of Systematic Reviews. 2022 , 2022, 1-23		0
2	S3-Leitlinie Urtikaria. Teil 1: Klassifikation und Diagnostik der Urtikaria [Deutschsprachige Adaptation der internationalen S3-Leitlinie. 2023 , 21, 81-95		0
1	S3 Guideline Urticaria. Part 1: Classification and diagnosis of urticaria [German-language adaptation of the international S3 Guideline. 2023 , 21, 81-93		0